Guide
Wegovy Savings Card 2026: The One Condition Most People Fail
The card can reach $0 to $25 a month, but only for commercial plans that already cover Wegovy for weight management. It reduces a copay rather than acting as a coupon, an
The card can reach $0 to $25 a month, but only for commercial plans that already cover Wegovy for weight management. It reduces a copay rather than acting as a coupon, and federal law bars it entirely on Medicare, Medicaid, TRICARE and the VA.
What does the comparison actually show?
| Your situation | What you pay | Why |
|---|---|---|
| Commercial plan that covers Wegovy | $0–$25 | The card reduces an existing copay |
| Commercial plan that excludes weight-loss drugs | ~$650 | A separate non-covered tier |
| Medicare or Medicaid | Card barred | Federal law. Use the Bridge at ~$50 |
| No insurance | $349 | NovoCare direct, or $149 for the approved oral tablet |
Not the diagnosis. Whether your plan covers the drug at all. A large share of employer plans still exclude obesity medications, and the card is a copay-reduction layer rather than a standalone discount.
One call answers it: “Is Wegovy on my formulary for chronic weight management, and at what tier?”
If it is excluded, the useful comparison is $650 on the non-covered tier against $349 through NovoCare, $149 for the approved oral tablet, or $145 for the cheapest compounded semaglutide programme we captured.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does each route cost?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $186 | $2,232 | Captured at source |
| Compounded, month-to-month, flat | $215 | $2,580 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is the Wegovy savings card really $25 a month?
For commercial plans that cover Wegovy for weight management, it can reach $0 to $25. If the plan excludes weight-loss drugs you fall to a non-covered tier at roughly $650.
Can I use it on Medicare?
No. Federal law bars manufacturer copay cards on any Medicare-paid drug. The GLP-1 Bridge at about $50 is the Medicare route.
What if my plan excludes weight-loss drugs?
The realistic comparison becomes $650 on the non-covered tier against $349 through NovoCare, $149 for the approved oral tablet, or cash-pay compounded.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Ro Body vs Hims & HersComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Brand-Name vs Compounded GLP-1Comparisons
- Zepbound vs MounjaroComparisons
- Zepbound vs Compounded TirzepatidePillar / Money
- Zepbound vs Compounded TirzepatideComparisons
- Tirzepatide Cost in 2026Pillar / Money
Related coverage
- Weight-Loss Percentage Calculator
- Zepbound savings: every route
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Storing and Travelling With a GLP-1: Cold Chain, Airports and What Breaks
- Switching GLP-1 Providers: The Practical and Clinical Steps
- Terms of Use
- Tirzepatide 3-Month Plans: What the Middle Term Actually Saves
- Tirzepatide Alternatives 2026: Nine Options, Ranked by What You Are Solving
GLP-1 Tirzepatide Rank. “Wegovy Savings Card 2026: The One Condition Most People Fail.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/wegovy-savings-card-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.